Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

British Journal of Cancer

Volumn 107, Issue 7, 2012, Pages 1093-1099

  Naing, A ^a   Aghajanian, C ^b   Raymond, E ^c   Olmos, D ^d   Schwartz, G ^b   Oelmann, E ^e   Grinsted, L ^e   Burke, W ^e   Taylor, R ^e   Kaye, S ^d   Kurzrock, R ^a   Banerji, U ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c BEAUJON HOSPITAL   (France)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

Author keywords

AZD8055; mTOR inhibitors; phase I

Indexed keywords

AZD 8055; FLUORODEOXYGLUCOSE F 18; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; LYMPHOMA; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; STOMATITIS;

ADULT; AGED; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORPHOLINES; MULTIPROTEIN COMPLEXES; NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84866928171     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.368     Document Type: Article

References (24)

1. Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E (2010) New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs 19: 919-930
2. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'Reilly T, Stolz B, Marti A, Thomas G, Lane HA (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64: 252-261
3. Carew JS, Kelly KR, Nawrocki ST (2011) Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol 6: 17-27
4. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P, James D, Howard Z, Dudley P, Hughes G, Smith L, Maguire S, Hummersone M, Malagu K, Menear K, Jenkins R, Jacobsen M, Smith GC, Guichard S, Pass M (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70: 288-298
5. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL (2008) Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTENdeficient glioblastoma. PLoS Med 5: e8 de
6. Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van TH, Pruim J, Brans B, Leffers P, Dingemans AM, Smit EF, Groen HJ, Hoekstra OS (2011) Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. J Nucl Med 52: 48-55
7. Europeans Medicines Agency (2011) Temsirolimus Summary of Product Characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000799/WC500039912.pdf 19 September 2011, accessed 23 February 2012
8. Europeans Medicines Agency (2012) Everolimus Summary of Product Characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/001038/WC500022814.pdf 1 January 2012, accessed 23 February 2012
9. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688
10. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7: e38
11. Fuster D, Ayuso JR, Poveda A, Cubedo R, Casado A, Martinez-Trufero J, Lopez-Pousa A, DelMuro XG, Lomena F, Maurel J, Pons F (2011) Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study. Q J Nucl Med Mol Imaging 55: 680-687
12. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22
13. Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE (2009) Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 114: 2926-2935
14. Kong D, Yamori T (2009) Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr Med Chem 16: 2839-2854
15. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627-644
16. O'Donnell A, Faivre S, Burris III HA, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26: 1588-1595
17. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508
18. Oberstein PE, Saif MW (2012) Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clin Med Insights Oncol 6: 41-51
19. Pal SK, Reckamp K, Yu H, Figlin RA (2010) Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 19: 1355-1366
20. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, Armand JP (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22: 2336-2347
21. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159-168
22. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284: 8023-8032
23. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501
24. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35: 1773-1782